Last update Sept. 4, 2022
It is a prokinetic from the benzamide group, a dopamine antagonist and similar to Metoclopramide, but with higher extrapyramidal side-effects (Serrano 1999, Cuena 1998, Jiménez 1996) and poorly known pharmacokinetics. It is used to treat nausea, vomiting, and other gastrointestinal disorders. Oral administration three times a day, or intravenously.
At latest update, relevant published data on excretion into breast milk were not found.
The scarcity of known pharmacokinetic data does not allow to predict the magnitude of its possible excretion in breast milk.
As with Metoclopramide it can produce increased secretion of Prolactin and galactorrhea. (AEMPS 2014, Perez 1980)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM